{"entity":{"id":"nct07324629","kind":"trial","name":"Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic Carcinoma","aka":[],"tldr":"A phase 2 trial of Sacituzumab tirumotecan in thymoma and thymic carcinoma, run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., now recruiting.","summary":"Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic Carcinoma is a phase 2 interventional study registered as NCT07324629 by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., with 30 participants planned, started 2026-03-13 and due to reach its primary completion in 2028-04. Interventions recorded: Sacituzumab tirumotecan.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07324629","url":"https://clinicaltrials.gov/study/NCT07324629"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["thymic-epithelial"],"sections":[],"technologies":[],"targets":[],"drugs":["sacituzumab-tirumotecan"],"companies":["kelun-biotech"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07324629","phase":"2","setting":"A Phase II Clinical Study of Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic Carcinoma With Treatment Failure After Platinum-Based Therapy","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","enrolled":30,"outcomes":[]},"route":"/trials/nct07324629/","neighbours":{"cancer":[{"id":"thymic-epithelial","kind":"cancer","name":"Thymoma and thymic carcinoma","route":"/cancers/thymic-epithelial/"}],"drug":[{"id":"sacituzumab-tirumotecan","kind":"drug","name":"Sacituzumab tirumotecan","route":"/drugs/sacituzumab-tirumotecan/"}],"company":[{"id":"kelun-biotech","kind":"company","name":"Sichuan Kelun-Biotech","route":"/companies/kelun-biotech/"}]}}